10/26/2009

The FDA has issued an emergency-use authorization that allows doctors to administer peramivir, an antiviral drug developed by BioCryst Pharmaceuticals, in patients with H1N1 influenza. The approval limits the use of the product to patients who do not respond to Tamiflu or Relenza.

Related Summaries